739 related articles for article (PubMed ID: 29859132)
1. A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations - results of a prematurely terminated study.
Kalimuddin S; Chan YFZ; Phillips R; Ong SP; Archuleta S; Lye DC; Tan TT; Low JGH
Trials; 2018 Jun; 19(1):305. PubMed ID: 29859132
[TBL] [Abstract][Full Text] [Related]
2. Vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: study protocol for a phase IIB randomized controlled trial.
Kalimuddin S; Phillips R; Gandhi M; de Souza NN; Low JG; Archuleta S; Lye D; Tan TT
Trials; 2014 Jun; 15():233. PubMed ID: 24943129
[TBL] [Abstract][Full Text] [Related]
3. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
Moore CL; Osaki-Kiyan P; Haque NZ; Perri MB; Donabedian S; Zervos MJ
Clin Infect Dis; 2012 Jan; 54(1):51-8. PubMed ID: 22109947
[TBL] [Abstract][Full Text] [Related]
4. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
Claeys KC; Zasowski EJ; Casapao AM; Lagnf AM; Nagel JL; Nguyen CT; Hallesy JA; Compton MT; Kaye KS; Levine DP; Davis SL; Rybak MJ
Antimicrob Agents Chemother; 2016 Oct; 60(10):5841-8. PubMed ID: 27431221
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.
Moise PA; Culshaw DL; Wong-Beringer A; Bensman J; Lamp KC; Smith WJ; Bauer K; Goff DA; Adamson R; Leuthner K; Virata MD; McKinnell JA; Chaudhry SB; Eskandarian R; Lodise T; Reyes K; Zervos MJ
Clin Ther; 2016 Jan; 38(1):16-30. PubMed ID: 26585355
[TBL] [Abstract][Full Text] [Related]
6. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study.
Murray KP; Zhao JJ; Davis SL; Kullar R; Kaye KS; Lephart P; Rybak MJ
Clin Infect Dis; 2013 Jun; 56(11):1562-9. PubMed ID: 23449272
[TBL] [Abstract][Full Text] [Related]
7. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study.
Arshad S; Huang V; Hartman P; Perri MB; Moreno D; Zervos MJ
Int J Infect Dis; 2017 Apr; 57():27-31. PubMed ID: 28131729
[TBL] [Abstract][Full Text] [Related]
8. Impact of Molecular Epidemiology and Reduced Susceptibility to Glycopeptides and Daptomycin on Outcomes of Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia.
Lee HY; Chen CL; Liu SY; Yan YS; Chang CJ; Chiu CH
PLoS One; 2015; 10(8):e0136171. PubMed ID: 26295150
[TBL] [Abstract][Full Text] [Related]
9. Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Kullar R; Davis SL; Kaye KS; Levine DP; Pogue JM; Rybak MJ
Pharmacotherapy; 2013 Jan; 33(1):3-10. PubMed ID: 23307539
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin or Daptomycin Plus a β-Lactam Versus Vancomycin or Daptomycin Alone for Methicillin-Resistant
Yi YH; Wang JL; Yin WJ; Xu WH
Microb Drug Resist; 2021 Aug; 27(8):1044-1056. PubMed ID: 33728980
[No Abstract] [Full Text] [Related]
11. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.
Tong SYC; Lye DC; Yahav D; Sud A; Robinson JO; Nelson J; Archuleta S; Roberts MA; Cass A; Paterson DL; Foo H; Paul M; Guy SD; Tramontana AR; Walls GB; McBride S; Bak N; Ghosh N; Rogers BA; Ralph AP; Davies J; Ferguson PE; Dotel R; McKew GL; Gray TJ; Holmes NE; Smith S; Warner MS; Kalimuddin S; Young BE; Runnegar N; Andresen DN; Anagnostou NA; Johnson SA; Chatfield MD; Cheng AC; Fowler VG; Howden BP; Meagher N; Price DJ; van Hal SJ; O'Sullivan MVN; Davis JS;
JAMA; 2020 Feb; 323(6):527-537. PubMed ID: 32044943
[TBL] [Abstract][Full Text] [Related]
12. Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches.
Holubar M; Meng L; Deresinski S
Infect Dis Clin North Am; 2016 Jun; 30(2):491-507. PubMed ID: 27208769
[TBL] [Abstract][Full Text] [Related]
13. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia.
Wi YM; Kim JM; Joo EJ; Ha YE; Kang CI; Ko KS; Chung DR; Song JH; Peck KR
Int J Antimicrob Agents; 2012 Aug; 40(2):108-13. PubMed ID: 22633565
[TBL] [Abstract][Full Text] [Related]
14. Influence of early daptomycin therapy on treatment outcome of meticillin-resistant Staphylococcus aureus bacteraemia with high vancomycin minimum inhibitory concentrations.
Cheng CW; Hsu PC; Yang CC; Chang HJ; Siu LK; Wu TL; Huang CT; Lee MH
Int J Antimicrob Agents; 2013 Mar; 41(3):293-4. PubMed ID: 23312599
[No Abstract] [Full Text] [Related]
15. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.
Ahmad NM; Rojtman AD
Ann Pharmacother; 2010 May; 44(5):918-21. PubMed ID: 20354160
[TBL] [Abstract][Full Text] [Related]
16. Vancomycin and daptomycin minimum inhibitory concentrations as a predictor of outcome of methicillin-resistant Staphylococcus aureus bacteraemia.
Ruiz J; Ramirez P; Concha P; Salavert-Lletí M; Villarreal E; Gordon M; Frasquet J; Castellanos-Ortega Á
J Glob Antimicrob Resist; 2018 Sep; 14():141-144. PubMed ID: 29601996
[TBL] [Abstract][Full Text] [Related]
17. CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.
Tong SY; Nelson J; Paterson DL; Fowler VG; Howden BP; Cheng AC; Chatfield M; Lipman J; Van Hal S; O'Sullivan M; Robinson JO; Yahav D; Lye D; Davis JS;
Trials; 2016 Mar; 17():170. PubMed ID: 27029920
[TBL] [Abstract][Full Text] [Related]
18. Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial.
Cheng MP; Lawandi A; Butler-Laporte G; Paquette K; Lee TC
Trials; 2018 May; 19(1):297. PubMed ID: 29843781
[TBL] [Abstract][Full Text] [Related]
19. Use of daptomycin to treat infections with methicillin-resistant Staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1.5 to 2 μg/mL.
McDaneld PM; Spooner LM; Mohr JF; Belliveau PP
Ann Pharmacother; 2013 Dec; 47(12):1654-65. PubMed ID: 24259618
[TBL] [Abstract][Full Text] [Related]
20. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
